Similarly, treatment with lactate dehydrogenase inhibitors (LDHi) reduces tumor cell glucose uptake and expression of the glucose transporter GLUT1, improving the tumor-killing function of T cells and dampening Treg immunosuppressive activity. Here, SLC2A1 is linked to neoplasm.